Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imbruvica Gets Broad CLL Okay in EU But Draft Rebuff From UK's NICE

Executive Summary

AbbVie Inc. and Johnson & Johnson's Imbruvica (ibrutinib) has won a broader chronic lymphocytic leukemia (CLL) label in Europe but given a draft rebuff from NICE due to data ambiguity and told instead to file for inclusion in the UK's controversial government-funded Cancer Drugs Fund.

You may also be interested in...



NICE Backs Imbruvica In CLL On Price Cut Despite Outcome Uncertainties

It looks likely AbbVie. and Johnson & Johnson's Imbruvica (ibrutinib) will be made routinely available on the NHS in England and Wales for treating chronic lymphocytic leukemia after an undisclosed price cut was offered and data further considered by the UK HTA NICE.

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Novo Nordisk, Evotec Link Around Chronic Kidney Disease

Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel